Tim McCarthy, ImmuPharma’s Chairman, talks to Proactive Investors on the transformational Lupuzor™ licensing deal with US Avion Pharmaceuticals

ImmuPharma PLC‘s (LON:IMM) chairman Tim McCarthy caught up with Proactive’s Andrew Scott to talk through the recently announced licensing deal worth almost US$100mln for Lupuzor –  its treatment for the autoimmune disease lupus.

US speciality drugs group Avion Pharmaceuticals will fund the US$25mln costs of a phase III clinical trial next year.